Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Joan Tymon‐Rosario, Paola Manara, Diego Manavella, Stefania Bellone, Tobias M.P. Hartwich, Justin Harold, Yang Yang‐Hartwich, Margherita Zipponi, Jungmin Choi, Kyungjo Jeong, Levent Mutlu, Yi Yang, Gary Altwerger, Gulden Menderes, Elena Ratner, Gloria S. Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E. Schwartz, Ludmil B. Alexandrov, Alessandro D. Santin